Oculis Holding AG (OCS) Change in Receivables (2025 - 2026)

Oculis Holding AG (OCS) recorded quarterly Change in Receivables of -$1277.0 in Q1 2026, up 96.41% quarter-over-quarter from -$35592.0 in Q1 2025, and up 96.41% on a YoY basis from -$650.17 in Q1 2025.

Oculis Holding AG (OCS) Change in Receivables (2025 - 2026) Analysis & Trends

Oculis Holding AG's Change in Receivables history runs 2 years deep, the most recent figure standing at -$1277.0 for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - 22,529.00
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn -39.80 Mn
9 Abivax 90.15 Bn 90.15 Bn - -4.08 Mn
10 Oculis Holding AG 8.23 Bn 7.92 Bn - -1,277.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -1,277.00
Mar 31, 2026 -1,277.00
Mar 31, 2025 -35,592.02
Mar 31, 2025 -35,592.02